Pharmacogenomics (PGx) Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 – WaterCloud News

Posted on by

Other

In addition, the report categorizes product type and end uses as dynamic market segments that directly impact the growth potential and roadmap of the target market. The report highlights the core developments that are common to all regional hubs and their subsequent impact on the holistic growth path of the Pharmacogenomics (PGx) market worldwide. Other valuable aspects of the report are the market development history, various marketing channels, supplier analysis, potential buyers and the analysis of the markets industrial chain.

Ask For Discounts @ https://www.marketresearchintellect.com/ask-for-discount/?rid=225772&utm_source=WCS&utm_medium=888

Table of Content

1 Introduction of Pharmacogenomics (PGx) Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Pharmacogenomics (PGx) Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Pharmacogenomics (PGx) Market, By Deployment Model

5.1 Overview

6 Pharmacogenomics (PGx) Market, By Solution

6.1 Overview

7 Pharmacogenomics (PGx) Market, By Vertical

7.1 Overview

8 Pharmacogenomics (PGx) Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Pharmacogenomics (PGx) Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=225772&utm_source=WCS&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Tags: Pharmacogenomics (PGx) Market Size, Pharmacogenomics (PGx) Market Trends, Pharmacogenomics (PGx) Market Growth, Pharmacogenomics (PGx) Market Forecast, Pharmacogenomics (PGx) Market Analysis Sarkari result, Government Jobs, Sarkari naukri, NMK, Majhi Naukri,

View post:
Pharmacogenomics (PGx) Market Research Report 2020: Key Players, Applications, Drivers, Trends and Forecast to 2026 - WaterCloud News

Global Cancer Molecular Biomarkers Market to Register Growth in Incremental Opportunity after COVID-19 pandemic and Forecast 2015 to 2021 – Cole of…

Posted on by

Cancer molecular biomarkers refer to naturally-occurring molecules or genes in living organisms, which is an indicator for the presence of cancer in the body. A biomarker is a measurable indicator of biological process, condition, or disease and can be found in the blood, tissues, or other body fluids. Cancer molecular biomarkers help to diagnose cancer and monitor patients responses to treatments. On the basis of diagnostics, the cancer molecular biomarkers market can be segmented into immunoassays, immunohistochemical (IHC) tests, genetic and genomic markers, proteomics, flow cytometry, stem cell markers, monoclonal antibodies, pharmacogenomics, DNA microarrays, and IVD multivariate index assays (IVDMIA).

To remain ahead of your competitors, request for a sample [emailprotected] https://www.persistencemarketresearch.com/samples/3841

On the basis of discovery , the cancer molecular biomarkers market can be segmented into genetic methods, protein methods, and imaging. Genetic methods include DNA arrays, southern blot, polymerase chain reaction (PCR), fluorescent in situ hybridization (FISH), and reverse transcriptase polymerase chain reaction (RT-PCR). Protein methods include immunohistochemistry (IHC) and mass spectrometry (MS). Imaging methods include positron emission tomography (PET), computed tomography (CT), magnetic resonance spectroscopy (MRS), x-ray, ultrasound, magnetic resonance imaging (MRI), and biophotonics.

North America has the largest market for cancer molecular biomarkers due to the growing IT industry, technological advancements, rise in the incidences of cancer, growing spending from government and private healthcare organizations, and improved healthcare infrastructure in this region.The North America market for cancer molecular biomarkers is followed by Europe. Asia is expected to witness high growth rate in thecancer molecular biomarkers market in the next few years due toincreasing research and development activities, rise in government intervention, growing awareness regarding cancer molecular biomarkers, and improving healthcare infrastructurein the region.

How the Coronavirus Threat has Taken Global Business into Uncharted Waters

Factors such as technological advancements, increasing research and development activities, increase in funding from various government and non-government organizations, rise in healthcare expenditure, non invasive technology, increasing incidences of cancer, and streamlined drug delivery process are expected to drive the market for cancer molecular biomarkers .In addition, growing survival rates and increased accuracy of diagnosis with the help of biomarkers are expected to drive market for cancer molecular biomarkers. However, issues related to reimbursement, high cost of diagnosis, requirement of immediate processing , lack of awareness, and various validation issues aresome of the major factors restraining growth of the globalcancer molecular biomarkers market.

Growing populationand economies in developing countries such as India and China is expected to drive growth of thecancer molecular biomarkers market in Asia. In addition,despite high cost involved in R&D, pharmaceutical companies are showing increased interest in this field and innovations along with technological advancement such as emergence of genetic based in vitro diagnostics, enhanced therapeutic effectiveness and decrease in the severity of the adverse effects are expected to offer new opportunities for global cancer molecular biomarkers market .

To receive extensive list of important regions, ask for TOC here @ https://www.persistencemarketresearch.com/toc/3841

Increasing number of mergers and acquisitions, risingnumber of collaborations, and product launches are some of the latest trends in the global cancer molecular biomarkers market.

Some of the major companies operating in the global cancer molecular biomarkers market are ,

For in-depth competitive analysis, Check Pre-Book here @ https://www.persistencemarketresearch.com/checkout/3841

Key geographies evaluated in this report are:

Key features of this report

Go here to see the original:
Global Cancer Molecular Biomarkers Market to Register Growth in Incremental Opportunity after COVID-19 pandemic and Forecast 2015 to 2021 - Cole of...

The Economic Impact of Coronavirus on The Leading Companies Competing in the Pharmacogenomic (PGx) Testing Market: Industry Forecast, 2018 to 2028 -…

Posted on by

COVID-19 Analysis on the Global Pharmacogenomic (PGx) Testing Market

A recent market research report on the Pharmacogenomic (PGx) Testing market published by Fact.MR is an in-depth assessment of the current landscape of the market. Further, the report elaborates on the impact of the COVID-19 on the Pharmacogenomic (PGx) Testing market and provides a thorough understanding of the growth potential of each market segment over the forecast period (2020-2030).

According to the analyst at Fact.MR, the Pharmacogenomic (PGx) Testing market is evenly slated to register a CAGR growth of ~XX% during the assessment period and attain a value of ~US$ XX by the end of 2030. The report analyzes the micro and macro-economic factors that are projected to impact the growth of the Pharmacogenomic (PGx) Testing market in the upcoming years. Further, a detailed analysis of the business continuity strategies of leading market participants is enclosed in the presented report.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=3143

Key Insights Enclosed in the Report

Segmentation of the Pharmacogenomic (PGx) Testing Market

The presented report dissects the Pharmacogenomic (PGx) Testing market into different segments and ponders over the current and future prospects of each segment. The report depicts the year-on-year growth of each segment and touches upon the different factors that are likely to influence the growth of each market segment. Further, projections are made taking into account the impact of the COVID-19 pandemic on the each market segment.

The various segments of the Pharmacogenomic (PGx) Testing market analyzed in the report include:

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=3143

Important doubts related to the Pharmacogenomic (PGx) Testing market clarified in the report:

Why Choose Fact.MR

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=3143

Continue reading here:
The Economic Impact of Coronavirus on The Leading Companies Competing in the Pharmacogenomic (PGx) Testing Market: Industry Forecast, 2018 to 2028 -...

GPs receive millions to further general practice – RACGP

Posted on by

News

Professor Jon Emery and Associate Professor Jason Ong speak to newsGP about their respective research.

Early cancer detection, pharmacogenomic testing for more effective antidepressant prescribing, HIV prevention.Two GPs have received sought-after grants to conduct research that has the potential to dramatically alter the way healthcare is provided, showing the scope of general practice.Among the recipients is Professor Jon Emery, GP and Herman Professor of Primary Care Cancer Research at the University of Melbourne and Western Health. He has been awarded a National Health and Medical Research Council (NHMRC) Investigator Grant of $2,360,520 for his project Transforming early detection of cancer in primary care.Over five years, the project will seek to transform approaches for the early detection of cancers in primary care through advances in computer-aided diagnosis and use of new genetic tests to identify patients at increased risk of cancer.We know that there are quite a few patients whose cancer diagnosis is delayed, and for a variety of reasons, Professor Emery told newsGP.Sometimes its by virtue of the nature of the complexity and vagueness of symptoms.Professor Emerys team will draw on data from existing electronic medical records to look at patterns of visits, test results and prescribing in order to develop sophisticated diagnostic algorithms for support tool Future Health Today, which identifies patients that GPs should consider for further investigation.The decision support tool is partly to flag patients who are returning with repeated, but subtle symptoms, Professor Emery said.But also, often abnormal test results are not always followed up and some are abnormal results that have only recently been identified as being associated with an increased risk of a cancer diagnosis.Probably the most interesting one is raised platelet count that we know is a marker of a number of cancers.The secondary aspect of the project will focus on using genomic testing to assess a patients risk of developing bowel cancer over 10 years to then tailor screening tests and prevention.That might prompt GPs to commence screening earlier, for example in their 40s, or potentially to delay screening because theyre actually at lower risk, Professor Emery explains.There are a number of polygenic risk scores for a number of other cancers, and well be gradually looking at how you might then start to implement a single test that would actually determine your risk.Professor Emery has also been named a recipient of one of 30 Medical Research Future Fund (MRFF) grants, for the sum of $1.39 million, to explore another aspect of genomics.His team will run a controlled clinical trial, investigating the effects of pharmacogenomics to prescribe antidepressants in primary care for patients with major depressive disorder.Its been known for some time that there are common genetic variants that determine the way we metabolise a number of different commonly prescribed drugs, Professor Emery said.Therefore that affects your responses either in terms of your risk of developing side effects or whether you actually require a larger dose to actually achieve the therapeutic response. Antidepressants are a good example of this.So [its] really looking at the impact of using pharmacogenomic tests to tailor both dosage and selection of antidepressant, and the impact that has on resolution of depressive symptoms.Associate Professor Jason Ong, a sexual health physician and post-doctoral research fellow at Monash University, was the other GP recipient of an NHMRC grant, receiving more than $1.5 million for his research project Leaving no one behind: community-driven approaches to eliminate HIV in Australia.While new HIV infections are declining in Australian-born men, he noted inequities within the statistics that showed numbers on the rise among overseas-born Australian men.A lot of times these people are still closeted, so they havent come out to their communities and even to GPs they may not identify themselves as gay or at risk for HIV, Associate Professor Ong told newsGP.So over the next five years, the project is looking at how we can better serve this group. How do we as the primary care workforce reach these people?He believes the missing link in HIV policy is direct community input, which he will seek to obtain through his project using the methodology of crowdsourcing.Its basically the idea of getting wisdom from the crowds. We get ideas from the affected community and then we develop those ideas rather than imposing certain policies, Associate Professor Ong explains.Through the project, he will also seek greater community involvement when it comes to testing for sexually transmitted diseases (STDs) through the application of a Pay It Forward system, which Associated Professor Ong successfully trialled in China.It usually costs about US$22 to do a test, which is very expensive for the Chinese. So we ran a trial where told patients You can actually test for STDs for free. Because someone cares for you, they paid for you. Then after theyve done the test, we give them the option Do you also want to pay it forward?, he said.The theory is that if it does work, it kind of goes viral and people just pay for each other.Ill be using activities like this, trying to get the community to also participate, rather than doctors just saying that you should do an HIV test.It was while working as a general practice registrar at a clinic focusing on sexual minorities that Associate Professor Ongs interest in sexual health developed.I never really thought about that as GP, but it certainly sparked some interest in how there are quite specific needs in that population, but also there are ways that GPs can provide that holistic care, he said.Thats the strength of a GP its not just talking about sexual health, its the holistic person, dealing with their mental health, substance use, and all sorts of things.In fact, HIV is not diagnosed by the specialists, its actually the GPs that diagnose most of the HIV cases in Australia. So theres a need to harness this workforce and also get them to think outside the box.While the majority of healthcare is delivered through general practice, with 84% of the population seeing a GP at least once each year, a much smaller proportion of NHMRC funding is allocated to GPs.As such, Professor Emery says GPs are well placed to provide even greater insights.We also need to be supporting other types of research. Maybe thats using existing data from general practice so that we really understand what contributes to high quality care where there are potential evidence gaps in the way that care is being provided, he said.That requires us to be supporting this concept of practice-based research networks.Log in below to join the conversation.

cancer general practice research HIV mental health NHMRC Investigator Grants sexual health

See the article here:
GPs receive millions to further general practice - RACGP

Molecular Diagnostics Market Growth Forecast and Segmentation based on Industry-wise 2022 – The Daily Chronicle

Posted on by

Molecular Diagnostics Market is worth USD 5.44 billion in 2014 and is expected to reach USD 11.04 billion by 2022, at a CAGR of 9.3% from 2014 to 2022.

The global molecular diagnostics market report offers in-depth analysis of the market size (revenue), market share, major market segments, different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and challenges in the molecular diagnostics market.

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10325645

KEY BENEFITS OF THE REPORT:Extensive evaluation of all the market dynamics that will impact this market during the forecast periodGranular understanding of the historical market trend and the resultant market forecastDeeper understanding of the behavior of the key players and innovators influencing this market

KEY PREMIUM INDUSTRY INSIGHTS:Growing prevalence of chronic diseases, the increased usage of the biomarkers, high demand for the personalized medicines, and the rapid technology advancements are the major drivers for the molecular diagnostics market.

According to the World Health Organization, by 2020, chronic diseases are estimated to account for around 58% of the global burden of disease and 60% of this burden will occur in the emerging countries. The governments are keen on controlling and preventing these diseases by putting greater emphasis on preventive health solutions and personalized care.

Various advancements in precise detection and diagnoses of disease will help reduce the cost of treating these chronic conditions. The molecular diagnostics market is set to increase exponentially in the future.

Molecular diagnostics techniques lead to the development of the advanced diagnostics and blood screening platforms and tests. They also help to develop a better understanding of the nature of chronic diseases and devise pathways to develop personalized treatments.However, the regulatory landscape and reimbursement issue are the major restraints for the global market.

Applications of molecular diagnostics in cancer management and pharmacogenomics will present the major opportunities for this market. The shift in technology such as point of care will further boost this market.

MARKET SEGMENTATION:This report analyzes the molecular diagnostics market by the following segments:

Molecular Diagnostics Market, by ProductsReagents and ConsumablesInstruments and SystemsMolecular Diagnostics Market, by TechnologiesPolymerase Chain Reaction (PCR)Immunochemical TechnologiesMicroarraysSequencingIsothermal Nucleic Acid Amplification Technology (INAAT)Other TechnologiesMolecular Diagnostics Market, by ApplicationsInfectious DiseasesOncologyGenetic Screening and TestingBlood ScreeningMicrobiologyOther Applications

Request For Full Report:https://www.kennethresearch.com/sample-request-10325645

KEY MARKET PLAYERS:Key players in the molecular diagnostics market include:

AbbottDanaher CorporationBecton, Dickinson and CompanyBioMerieux S.A.Grifols International, S.A.Hologic Inc.Qiagen N.V.F. Hoffmann-La Roche AGSiemens AGSysmex Corporation

<<<<>>>>Cloud Infrastructure Market Smart Cities Market IoT MarketLED MarketSmart Grid MarketVirtual Reality MarketAugmented Reality Market

About Kenneth Research

Kenneth Research is a reselling agency providing market research solutions in different verticals such as Automotive and Transportation, Chemicals and Materials, Healthcare, Food & Beverage and Consumer Packaged Goods, Semiconductors, Electronics & ICT, Packaging, and Others. Our portfolio includes set of market research insights such as market sizing and market forecasting, market share analysis and key positioning of the players (manufacturers, deals and distributors, etc), understanding the competitive landscape and their business at a ground level and many more. Our research experts deliver the offerings efficiently and effectively within a stipulated time. The market study provided by Kenneth Research helps the Industry veterans/investors to think and to act wisely in their overall strategy formulation

Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

More here:
Molecular Diagnostics Market Growth Forecast and Segmentation based on Industry-wise 2022 - The Daily Chronicle

DNA Diagnostics/Testing Market : Growth factor with key drivers, industry research, regional forecast – Cole of Duty

Posted on by

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global DNA Diagnostics/Testing market. It informs readers about key trends and opportunities in the global DNA Diagnostics/Testing market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global DNA Diagnostics/Testing market.

Key companies operating in the global DNA Diagnostics/Testing market include Abbott Laboratories, Affymetrix Inc., Agilent Technologies Inc, Applied Biosystems Group, Illumina Inc., Cepheid Inc., Hologic, Bio-Rad Laboratories, Dako, Abbott, Roche Diagnostics, Beckman Coulter Inc., Siemens Healthcare, etc.

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1760949/covid-19-impact-on-dna-diagnostics-testing-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global DNA Diagnostics/Testing market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global DNA Diagnostics/Testing Market Segment By Type:

,PCR Based Diagnostics,NGS DNA Diagnosis,In-situ Hybridization Diagnostics,Micro-arrays Based Diagnostics

Global DNA Diagnostics/Testing Market Segment By Application:

,Oncology Diagnostics & Histopathology,Identity Diagnostics & Forensics,Pharmacogenomics Diagnostic Testing & Drug Metabolism

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global DNA Diagnostics/Testing market.

Key companies operating in the global DNA Diagnostics/Testing market include Abbott Laboratories, Affymetrix Inc., Agilent Technologies Inc, Applied Biosystems Group, Illumina Inc., Cepheid Inc., Hologic, Bio-Rad Laboratories, Dako, Abbott, Roche Diagnostics, Beckman Coulter Inc., Siemens Healthcare, etc.

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1760949/covid-19-impact-on-dna-diagnostics-testing-market

TOC

1.1 Research Scope1.2 Market Segmentation1.3 Research Objectives1.4 Research Methodology1.4.1 Research Process1.4.2 Data Triangulation1.4.3 Research Approach1.4.4 Base Year1.5 Coronavirus Disease 2019 (Covid-19) Impact Will Have a Severe Impact on Global Growth1.5.1 Covid-19 Impact: Global GDP Growth, 2019, 2020 and 2021 Projections1.5.2 Covid-19 Impact: Commodity Prices Indices1.5.3 Covid-19 Impact: Global Major Government Policy1.6 The Covid-19 Impact on DNA Diagnostics/Testing Industry1.7 COVID-19 Impact: DNA Diagnostics/Testing Market Trends 2 Global DNA Diagnostics/Testing Quarterly Market Size Analysis2.1 DNA Diagnostics/Testing Business Impact Assessment COVID-192.1.1 Global DNA Diagnostics/Testing Market Size, Pre-COVID-19 and Post- COVID-19 Comparison, 2015-20262.2 Global DNA Diagnostics/Testing Quarterly Market Size 2020-20212.3 COVID-19-Driven Market Dynamics and Factor Analysis2.3.1 Drivers2.3.2 Restraints2.3.3 Opportunities2.3.4 Challenges 3 Quarterly Competitive Assessment, 20203.1 By Players, Global DNA Diagnostics/Testing Quarterly Market Size, 2019 VS 20203.2 By Players, DNA Diagnostics/Testing Headquarters and Area Served3.3 Date of Key Players Enter into DNA Diagnostics/Testing Market3.4 Key Players DNA Diagnostics/Testing Product Offered3.5 Mergers & Acquisitions, Expansion Plans 4 Impact of Covid-19 on DNA Diagnostics/Testing Segments, By Type4.1 Introduction1.4.1 PCR Based Diagnostics1.4.2 NGS DNA Diagnosis1.4.3 In-situ Hybridization Diagnostics1.4.4 Micro-arrays Based Diagnostics4.2 By Type, Global DNA Diagnostics/Testing Market Size, 2019-2021 5 Impact of Covid-19 on DNA Diagnostics/Testing Segments, By Application5.1 Overview5.5.1 Oncology Diagnostics & Histopathology5.5.2 Identity Diagnostics & Forensics5.5.3 Pharmacogenomics Diagnostic Testing & Drug Metabolism5.2 By Application, Global DNA Diagnostics/Testing Market Size, 2019-20215.2.1 By Application, Global DNA Diagnostics/Testing Market Size by Application, 2019-2021 6 Geographic Analysis6.1 Introduction6.2 North America6.2.1 Macroeconomic Indicators of US6.2.2 US6.2.3 Canada6.3 Europe6.3.1 Macroeconomic Indicators of Europe6.3.2 Germany6.3.3 France6.3.4 UK6.3.5 Italy6.4 Asia-Pacific6.4.1 Macroeconomic Indicators of Asia-Pacific6.4.2 China6.4.3 Japan6.4.4 South Korea6.4.5 India6.4.6 ASEAN6.5 Rest of World6.5.1 Latin America6.5.2 Middle East and Africa 7 Company Profiles7.1 Abbott Laboratories7.1.1 Abbott Laboratories Business Overview7.1.2 Abbott Laboratories DNA Diagnostics/Testing Quarterly Revenue, 20207.1.3 Abbott Laboratories DNA Diagnostics/Testing Product Introduction7.1.4 Abbott Laboratories Response to COVID-19 and Related Developments7.2 Affymetrix Inc.7.2.1 Affymetrix Inc. Business Overview7.2.2 Affymetrix Inc. DNA Diagnostics/Testing Quarterly Revenue, 20207.2.3 Affymetrix Inc. DNA Diagnostics/Testing Product Introduction7.2.4 Affymetrix Inc. Response to COVID-19 and Related Developments7.3 Agilent Technologies Inc7.3.1 Agilent Technologies Inc Business Overview7.3.2 Agilent Technologies Inc DNA Diagnostics/Testing Quarterly Revenue, 20207.3.3 Agilent Technologies Inc DNA Diagnostics/Testing Product Introduction7.3.4 Agilent Technologies Inc Response to COVID-19 and Related Developments7.4 Applied Biosystems Group7.4.1 Applied Biosystems Group Business Overview7.4.2 Applied Biosystems Group DNA Diagnostics/Testing Quarterly Revenue, 20207.4.3 Applied Biosystems Group DNA Diagnostics/Testing Product Introduction7.4.4 Applied Biosystems Group Response to COVID-19 and Related Developments7.5 Illumina Inc.7.5.1 Illumina Inc. Business Overview7.5.2 Illumina Inc. DNA Diagnostics/Testing Quarterly Revenue, 20207.5.3 Illumina Inc. DNA Diagnostics/Testing Product Introduction7.5.4 Illumina Inc. Response to COVID-19 and Related Developments7.6 Cepheid Inc.7.6.1 Cepheid Inc. Business Overview7.6.2 Cepheid Inc. DNA Diagnostics/Testing Quarterly Revenue, 20207.6.3 Cepheid Inc. DNA Diagnostics/Testing Product Introduction7.6.4 Cepheid Inc. Response to COVID-19 and Related Developments7.7 Hologic7.7.1 Hologic Business Overview7.7.2 Hologic DNA Diagnostics/Testing Quarterly Revenue, 20207.7.3 Hologic DNA Diagnostics/Testing Product Introduction7.7.4 Hologic Response to COVID-19 and Related Developments7.8 Bio-Rad Laboratories7.8.1 Bio-Rad Laboratories Business Overview7.8.2 Bio-Rad Laboratories DNA Diagnostics/Testing Quarterly Revenue, 20207.8.3 Bio-Rad Laboratories DNA Diagnostics/Testing Product Introduction7.8.4 Bio-Rad Laboratories Response to COVID-19 and Related Developments7.9 Dako7.9.1 Dako Business Overview7.9.2 Dako DNA Diagnostics/Testing Quarterly Revenue, 20207.9.3 Dako DNA Diagnostics/Testing Product Introduction7.9.4 Dako Response to COVID-19 and Related Developments7.10 Abbott7.10.1 Abbott Business Overview7.10.2 Abbott DNA Diagnostics/Testing Quarterly Revenue, 20207.10.3 Abbott DNA Diagnostics/Testing Product Introduction7.10.4 Abbott Response to COVID-19 and Related Developments7.11 Roche Diagnostics7.11.1 Roche Diagnostics Business Overview7.11.2 Roche Diagnostics DNA Diagnostics/Testing Quarterly Revenue, 20207.11.3 Roche Diagnostics DNA Diagnostics/Testing Product Introduction7.11.4 Roche Diagnostics Response to COVID-19 and Related Developments7.12 Beckman Coulter Inc.7.12.1 Beckman Coulter Inc. Business Overview7.12.2 Beckman Coulter Inc. DNA Diagnostics/Testing Quarterly Revenue, 20207.12.3 Beckman Coulter Inc. DNA Diagnostics/Testing Product Introduction7.12.4 Beckman Coulter Inc. Response to COVID-19 and Related Developments7.13 Siemens Healthcare7.13.1 Siemens Healthcare Business Overview7.13.2 Siemens Healthcare DNA Diagnostics/Testing Quarterly Revenue, 20207.13.3 Siemens Healthcare DNA Diagnostics/Testing Product Introduction7.13.4 Siemens Healthcare Response to COVID-19 and Related Developments 8 Key Findings 9 Appendix9.1 About US9.2 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Excerpt from:
DNA Diagnostics/Testing Market : Growth factor with key drivers, industry research, regional forecast - Cole of Duty

Precision Medicine Market 2020: Industry Analysis and Detailed Profiles of Top Industry Players are Neon Therapeutics, Moderna, Inc, Merck & Co.,…

Posted on by

Global Precision Medicine market report provides an in-depth overview of Product Specification, technology, product type and production analysis considering major factors such as Revenue, Cost, Gross and Gross Margin. The company profiles of all the key players and brands that are dominating the Precision Medicine market with moves like product launches, joint ventures, merges and accusations which in turn is affecting the sales, import, export, revenue and CAGR values are mentioned in the report. The report is generated based on the market type, size of the organization, availability on-premises and the end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa.

Global Precision Medicine Marketto grow with a substantial CAGR in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and accelerating demand of novel therapies to prevent of cancer related disorders are the key factors for lucrative growth of market

Key Market Players:

Few of the major competitors currently working in the global precision medicine market are Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC., F. Hoffmann-La Roche Ltd, CureVac AG, CELLDEX THERAPEUTICS, BIONTECH SE, Advaxis, Inc, GlaxoSmithKline plc, Bioven International Sdn Bhd, Agenus Inc., Immatics Biotechnologies GmbH, Immunovative Therapies, Bristol-Myers Squibb Company, Gritstone Oncology, NantKwest, Inc among others.

Download Free PDF Sample Copy of[emailprotected]http://databridgemarketresearch.com/request-a-sample/?dbmr=global-precision-medicine-market

Global Precision Medicine MarketBy Application (Diagnostics, Therapeutics and Others), Technologies (Pharmacogenomics, Point-of-Care Testing, Stem Cell Therapy, Pharmacoproteomics and Others), Indication (Oncology, Central Nervous System (CNS) Disorders, Immunology Disorders, Respiratory Disorders, Others), Drugs (Alectinib, Osimertinib, Mepolizumab,Aripiprazole lauroxil and Others), Route of Administration (Oral,Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Competitive Analysis:

The precision medicine market is highly fragmented and is based on new product launches and clinical results of products. Hence the major players have used various strategies such as new product launches, clinical trials, market initiatives, high expense on research and development, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of mass spectrometry market for global, Europe, North America, Asia Pacific and South America.

Market Drivers

Market Restraints

Talk to The Author of Report @http://databridgemarketresearch.com/speak-to-analyst/?dbmr=global-precision-medicine-market

Market Definition:

Precision medicines is also known as personalized medicines is an innovative approach to the patient care for disease treatment, diagnosis and prevention base on the persons individual genes. It allows doctors or physicians to select treatment option based on the patients genetic understanding of their disease.

According to the data published in PerMedCoalition, it was estimated that the USFDA has approved 25 novels personalized medicines in the year of 2018. These growing approvals annually by the regulatory authorities and rise in oncology and CNS disorders worldwide are the key factors for market growth.

Grab Your Report at an Impressive 30% Discount! Please click[emailprotected]https://www.databridgemarketresearch.com/request-a-discount/global-precision-medicine-market

Key Developments in the Market:

Competitive Analysis:

Global precision medicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of global precision medicine market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Market Segmentation:

By technology:-big data analytics, bioinformatics, gene sequencing, drug discovery, companion diagnostics, and others.

By application:- oncology, hematology, infectious diseases, cardiology, neurology, endocrinology, pulmonary diseases, ophthalmology, metabolic diseases, pharmagenomics, and others.

On the basis of end-users:- pharmaceuticals, biotechnology, diagnostic companies, laboratories, and healthcare it specialist.

On the basis of geography:- North America & South America, Europe, Asia-Pacific, and Middle East & Africa. U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil among others.

In 2017, North America is expected to dominate the market.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

Originally posted here:
Precision Medicine Market 2020: Industry Analysis and Detailed Profiles of Top Industry Players are Neon Therapeutics, Moderna, Inc, Merck & Co.,...

Global Pharmacogenomics Market is Poised To Achieve Continuing Growth During Forecast Period 2020-2027 – 3rd Watch News

Posted on by

The Global Pharmacogenomics Market report gives a detailed overview of the key market drivers, restraints, and trends and analyzes the way they will affect markets development over the forecast period 2020-2027

This Global Pharmacogenomics Industry 2020 report also gives comprehensive insight of , in-depth overview of the competitive landscape of the Pharmacogenomics Market, Industry Size, Share, Market Productions, Pricing, Global Revenues 2018-2020 Import-Export Figures & SWOT Analysis, PEST analysis, PORTER analysis and Forecast till 2027

Get/Download Free sample report,(Including COVID19 Impact Analysis, full TOC, Tables and Figures) @https://www.reportspedia.com/report/life-sciences/2015-2027-global-pharmacogenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58762#request_sample

Pharmacogenomics Market Influencing Factors:

Pharmacogenomics Market Forecast (2020-2027):

(Exclusive Offer: Up to 20% discount on this report):- Ask For Discount https://www.reportspedia.com/discount_inquiry/discount/58762

The leading players of Pharmacogenomics market includes

Bayer AGBecton, Dickinson and CompanyAffymetrix, Inc.F. Hoffmann-La Roche AGQIAGENAbbott Laboratories, Inc.Bio-Rad Laboratories, Inc.Thermo Fisher Scientific Inc.Illumina, Inc.AstraZeneca PLC

Pharmacogenomics Market Segmentation

Type Analysis of Pharmacogenomics Market:

DNA SequencingMicroarray, Polymerase Chain ReactionElectrophoresisMass SpectrometryOthers

Applications Analysis of Pharmacogenomics Market:

Drug DiscoveryTailored TreatmentOncologyPain ManagementOther Therapeutic Applications

Any Quries Or Customization? Do Inquiry Here https://www.reportspedia.com/report/life-sciences/2015-2027-global-pharmacogenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58762#inquiry_before_buying

Globally, Pharmacogenomics market spread across-

1. North America Country (United States, Canada)

2. South America

3. Asia Country (China, Japan, India, Korea)

4. Europe Country (Germany, UK, France, Italy)

5. Other Country (Middle East, Africa, GCC)

Segment 1. Pharmacogenomics Market Overview, Market Scope, Size Estimation, and Market Segmentation.

Segment 2. Pharmacogenomics Growth Drivers, Opportunities, Emerging Segments, and Industry Plans and Policies are explained.

Segment 3. Pharmacogenomics Industry Chain Analysis Explaining Manufacturing Base, Market Share, Product Type, Upstream Raw Materials Suppliers, and Downstream Buyers Is Covered.

Segment 4. Pharmacogenomics segmentation by type explains growth rate , and value from 2015-2020

Segment 5. Pharmacogenomics segmentation by application and regions covers consumption, growth rate, market share, price, and gross margin analysis.

Segment 6. Production, Consumption, Import-Export analysis of Pharmacogenomics by regions is explained.

Segment 7. Market Status and regional SWOT Analysis, PEST analysis, PORTER analysis are described.

Segment 8. Competitive landscape structure of top Pharmacogenomics players, gross margin analysis, price, and production value is specified.

Segment 9. Pharmacogenomics market analysis forecast by volume, value, consumption from 2020-2027 is provided for type, application, and region.

Segment 10. Pharmacogenomics Market maturity analysis, consumption forecast, feasibility study, and valuable Insight.

For more Information or Browse the complete report @https://www.reportspedia.com/report/life-sciences/2015-2027-global-pharmacogenomics-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/58762#table_of_contents

Go here to see the original:
Global Pharmacogenomics Market is Poised To Achieve Continuing Growth During Forecast Period 2020-2027 - 3rd Watch News

The Economic Impact of Coronavirus on Pharmacogenomic (PGx) Testing Market Poised to Expand at a Robust Pace Over 2018 to 2028 – Farmers Ledger

Posted on by

A recent study published by Fact.MR on the global Pharmacogenomic (PGx) Testing market offers an in-depth understanding of the overall prospects of the market. The study also broadly covers the impact of the novel COVID-19 pandemic on the Pharmacogenomic (PGx) Testing market and offers insights related to how market participants should align their business operations to mitigate losses and retain their foothold in the current market landscape. Further, the summary of the key findings of the research along with the megatrends influencing the growth of the Pharmacogenomic (PGx) Testing market is highlighted in the presented study. The market introduction and definition is included to help our readers understand the basic concepts of the study on the Pharmacogenomic (PGx) Testing market.

As per the report, the Pharmacogenomic (PGx) Testing market is set to grow at a CAGR of ~XX% over the forecast period (20XX-20XX) and reach a value of ~US$XX towards the end of 2029. The regional trade analysis along with the leading importers and exporters is included in the study. In addition, the supply-demand analysis and the key developments in the Pharmacogenomic (PGx) Testing market are highlighted in the report. Although the Pharmacogenomic (PGx) Testing market is slated to grow at a consistent pace during the forecast period, the COVID-19 pandemic is expected to dent the growth of the market particularly in 2020.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=3143

Important Findings of the Report

Segmentation of the Pharmacogenomic (PGx) Testing Market

This chapter of the report highlights the current market size (US$) and includes the volume analysis and forecast for various geographical regions.

The application analysis in the report offers a clear understanding of how the Pharmacogenomic (PGx) Testing is used in different applications.

This chapter of the report throws light on the supply-demand pattern for the different products within the Pharmacogenomic (PGx) Testing market.

Competitive landscape

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=3143

Important questions pertaining to the Pharmacogenomic (PGx) Testing market catered to in the report:

Reasons to Buy From Fact.MR

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=3143

Read this article:
The Economic Impact of Coronavirus on Pharmacogenomic (PGx) Testing Market Poised to Expand at a Robust Pace Over 2018 to 2028 - Farmers Ledger

Precision Medicine Software Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast-…

Posted on by

You will get latest updated report as per the COVID-19 Impact on this industry. Our updated reports will now feature detailed analysis that will help you make critical decisions.

The Global Precision Medicine Software Market is expected to grow by 2025 at a CAGR of 12.53%.

Rising prevalence of cancer across the world will significantly enhancement the market development within the forthcoming years. Increasing usage of biomarkers for personalized medicine cancer therapy and advancements within the next generation sequencing further propels the precision medicine market evolution positively. Growing prevalence of chronic and rare diseases propel the necessity to grow technologically advanced tools for rapid integration and analysis of patient data. The bioinformatics system assists in translation of knowledge to form effective clinical solutions. Henceforth, the increasing amount of knowledge within the healthcare system will boost the demand for bioinformatics, enhancing the precision medicine market demand. The event of bioinformatics solutions and software will propel immunotherapy development and enhance microbiome analysis thereby, advancing the sector of precision medicine. Additionally, the event of high throughput technologies like next generation sequencing and microarray will pave the way for bioinformatics market growth which will further drive the market demand within the upcoming years.

Browse Full Report here: https://www.marketresearchengine.com/precision-medicine-software-market

The global Precision Medicine Software market is segregated on the basis of Application as Rare Diseases, Pharmacogenomics, Oncology, and Other Applications. Based on End User the global Precision Medicine Software market is segmented in Pharmaceutical & Biotechnology Companies, Research Centers and Government Institutes, Healthcare Providers, and Other End Users. Based on Delivery Mode the global Precision Medicine Software market is segmented in Cloud-Based Delivery Mode and On-Premise Delivery Mode.

The global Precision Medicine Software market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Precision Medicine Software market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Competitive Rivalry

Human Longevity Inc, Translational Software Inc, Sunquest Information Systems Inc, Gene42 Inc, Lifeomic Health LLC , Syapse Inc, 2bprecise LLC, Fabric Genomics Inc, Foundation Medicine Inc, Sophia Genetics Sa, and others are among the major players in the global Precision Medicine Software market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Precision Medicine Software Market has been segmented as below:

Precision Medicine Software Market, By Application

Precision Medicine Software Market, By End User

Precision Medicine Software Market, By Delivery Mode

Precision Medicine Software Market, By Region

Precision Medicine Software Market, By Company

The report covers:

Report Scope:

The global Precision Medicine Software market report scope includes detailed study covering underlying factors influencing the industry trends.

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Precision Medicine Software market share. Major industry players with significant revenue share include Human Longevity Inc, Translational Software Inc, Sunquest Information Systems Inc, Gene42 Inc, Lifeomic Health LLC , Syapse Inc, 2bprecise LLC, Fabric Genomics Inc, Foundation Medicine Inc, Sophia Genetics Sa, and others.

Reasons to Buy this Report:

Customization

Customized report as per the requirement can be offered with appropriate recommendations

Request Sample Report here: https://www.marketresearchengine.com/precision-medicine-software-market

Table of Contents:

1.1 Key Insights

1.2 Report Overview

1.3 Markets Covered

1.4 Stakeholders

2.1 Research Scope

2.2 Market Research Process

2.3 Research Data Analysis

2.4.1 Secondary Research

2.4.2 Primary Research

2.4.3 Models for Estimation

2.5 Market Size Estimation

2.5.1 Bottom-Up Approach Segmental Market Analysis

2.5.2 Top-Down Approach Parent Market Analysis

4.1 Introduction

4.2.1 Drivers

4.2.2 Restraints

4.2.3 Opportunities

4.2.4 Challenges

4.2 Porters Five Force Analysis

5.1 Introduction

5.2 Rare Diseases

5.2.1 Market Overview

5.2.2 Market Size and Forecast

5.3 Pharmacogenomics

5.3.1 Market Overview

5.3.2 Market Size and Forecast

5.4 Oncology

5.4.1 Market Overview

5.4.2 Market Size and Forecast

5.5 Other Applications

5.5.1 Market Overview

5.5.2 Market Size and Forecast

6.1 Introduction

6.2 Pharmaceutical & Biotechnology Companies

6.2.1 Market Overview

6.2.2 Market Size and Forecast

6.3 Research Centers and Government Institutes

6.3.1 Market Overview

6.3.2 Market Size and Forecast

6.4 Healthcare Providers

6.4.1 Market Overview

6.4.2 Market Size and Forecast

6.5 Other End Users

6.5.1 Market Overview

6.5.2 Market Size and Forecast

7.1 Introduction

7.2 Cloud-Based Delivery Mode

7.2.1 Market Overview

7.2.2 Market Size and Forecast

7.3 On-Premise Delivery Mode

7.3.1 Market Overview

7.3.2 Market Size and Forecast

8.1 Introduction

8.2 North America

8.2.1 North America Precision Medicine Software, By Application

8.2.2 North America Precision Medicine Software, By End User

8.2.3 North America Precision Medicine Software, By Delivery Mode

8.3 Europe

8.3.1 Europe Precision Medicine Software, By Application

8.3.2 Europe Precision Medicine Software, By End User

8.3.3 Europe Precision Medicine Software, By Delivery Mode

8.4 Asia-Pacific

8.4.1 Asia-Pacific Precision Medicine Software, By Application

8.4.2 Asia-Pacific Precision Medicine Software, By End User

8.4.3 Asia-Pacific Precision Medicine Software, By Delivery Mode

8.5 Rest of the World

8.5.1 Rest of the World Precision Medicine Software, By Application

8.5.2 Rest of the World Precision Medicine Software, By End User

8.5.3 Rest of the World Precision Medicine Software, By Delivery Mode

9.1 Key Insights

9.2 Company Market Share Analysis

9.3 Strategic Outlook

9.3.1 Mergers & Acquisitions

9.3.2 New Product Development

9.3.3 Portfolio/Production Capacity Expansions

9.3.4 Joint Ventures, Collaborations, Partnerships & Agreements

Read the rest here:
Precision Medicine Software Market 2020: Challenges, Growth, Types, Applications, Revenue, Insights, Growth Analysis, Competitive Landscape, Forecast-...

Global Protein Detection and Quantitation Market Projected to Experience Major Revenue – 3rd Watch News

Posted on by

The GlobalProtein Detection and Quantitation Marketreport study includes an elaborative summary of the Protein Detection and Quantitation market that provides in-depth knowledge of various different segmentations. Protein Detection and Quantitation Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis of Protein Detection and Quantitation Market. The information includes the company profile, annual turnover, the types of products and services they provide, income generation, which provide direction to businesses to take important steps. Protein Detection and Quantitation delivers pin point analysis of varying competition dynamics and keeps ahead of Protein Detection and Quantitation competitors such as Thermo Fisher Scientific, Promega, Genecopoeia, Labome, Garland Science.

The report entitled GlobalProtein Detection and QuantitationMarket 2019 focuses on edging and imitate the key affecting components for the expansion of the market. It further proposes an intensive study of the market stature (revenue), market share, key market segments, distinct geographic regions, main market players, and prime industry trends. The point of this report is to depict the expected market patterns and revenue forecast for the global Protein Detection and Quantitation market for the following five years.

Get a piece of exclusive information to getProduct Specifications

The report global Protein Detection and Quantitation market records the essential market events comprehensive of product launches, mergers and acquisitions, technological advancement, and the brand new business outlines favored by driving business sector players. Worldwide Protein Detection and Quantitation Market Report additionally covers every single part of the business and the conspicuous market players present in particular countries examine the new advancement plans, advertise position, which will help in settling on essential business choices.

Key players featuring in Protein Detection and Quantitation market:

Global Protein Detection and Quantitation report covers particular aspects of the market including the product classification, product details, scope of uses and major geographical producing regions. The key districts overcast in Protein Detection and Quantitation report are the countries present in North America, Europe, APAC, South America, Middle East, and Africa.

Inquiry for Buying Report:https://www.marketresearchstore.com/report/global-protein-detection-and-quantitation-market-industry-trends-315809#InquiryForBuying

1.USA2.Europe3.Japan4.China5.India6.Southeast Asia

furthermore, the aspect that triggers and restricts the growth of the global Protein Detection and Quantitation industry is specified and simplify in depth in this research study. It helps experts in taking significant business choices to publicize their business. The study additionally examines regions having potentialities for future market development. It also gives data about developing markets, beneficial markets, static markets, declining markets, soaked markets or develop advertises along with development benefits.

1. The Outlook of the Protein Detection and Quantitation Industry2. Global Market Competition Landscape3. Global Protein Detection and Quantitation Market share4. Supply Chain Analysis5. Company Profiles6. Globalization & Trade7. Distributors and Customers8. Import, Export, Consumption and Consumption Value by Major Countries9. Global Protein Detection and Quantitation Market Forecast to 202410. Key success factors and Market Overview

In the end, the Protein Detection and Quantitation market collecting historical and recent data from various authentic resources and depending on all the factors and trends, the report presents a figurative estimate of the future market condition, along with compound annual growth rate (CAGR).

Read More Post:http://www.marketresearchstore.com/report/global-content-analytics-market-2018-by-manufacturers-regions-384474

Follow this link:
Global Protein Detection and Quantitation Market Projected to Experience Major Revenue - 3rd Watch News

The China Precision Medicine Industry Analysis by BIS Research projects the market to grow at a significant CAGR of 12.82% during the forecast period,…

Posted on by

China Precision Medicine Market to Reach $18,723. 5 Million by 2029. Key Questions Answered in this Report: What are the major market drivers, challenges, and opportunities in the China precision medicine market?

New York, May 23, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "China Precision Medicine Market: Focus on Ecosystems, Applications, and Competitive Landscape Analysis and Forecast, 2019-2029" - https://www.reportlinker.com/p05803973/?utm_source=GNW What are the underlying structures resulting in the emerging trends within the China precision medicine market? How will each segment of the China precision medicine market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2029? What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2019-2029? What are the key applications in China precision medicine market? What are the major segments of these applications? What are the major technologies that are employed in the China precision medicine market? Which is the current dominant technology? Who are the key manufacturers and service providers in the China precision medicine market, and what are their contributions? Moreover, what is the growth potential of each major precision medicine manufacturer and service provider?

China Precision Medicine Market Forecast, 2019-2029The China Precision Medicine Industry Analysis projects the market to grow at a significant CAGR of 12.82% during the forecast period, 2019-2029. The China precision medicine market generated $4,919.7 million revenue in 2018, in terms of value.

The China Precision Medicine market growth is majorly driven by factors such as shifting the significance in medicine from reaction to prevention, government initiatives for the incorporation of precision medicine in China, lowering costs and advancement in sequencing technologies, and surge in underlying direct-to-consumer (DTC) genetic testing market in China. However, factors such as fragmented healthcare system in China, a lack of knowledge dissemination for advanced diagnostic capabilities, and a lack of a unified framework for big data integration hamper the overall market growth.

Expert Quote on the China Precision Medicine MarketAnnouncement of the China Precision Medicine Initiative in 2016 has radically changed healthcare regimes in the country, with renewed focus being directed toward capitalizing the present genome sequencing boom in the country. Further, with the establishment of the China Precision Medicine Cloud by WuXi NextCODE and Huawei, cloud-based genomics is set to be the cornerstone of Chinas precision medicine revolution.

Scope of the Market Intelligence on China Precision Medicine MarketThe China precision medicine market research provides a gain a holistic view of the China precision medicine market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and services allied with the precision medicine market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, growth potential of each underlying sub-segment, and company, as well as other vital information with respect to China precision medicine market.

Market SegmentationThe China precision medicine market segmentation (on the basis of applied sciences) is further segmented into genomics, pharmacogenomics, and other applied sciences.Genomics is the prevalent applied sciences type in the China precision medicine market.

This segment constitutes the majority shareholder in the applied sciences ecosystem for precision medicine and is also expected to continue dominating through 2029.

The China precision medicine market segmentation (on the basis of digital health and information technology) is segmented into CDSS, big data analytics, IT infrastructure, genome informatics, in-silicon informatics, and mobile health.

The China precision medicine market segmentation (on the basis of application) is segmented into oncology, infectious diseases, neurology/psychiatry, lifestyle and endocrinology, cardiology, gastroenterology, and other applications.

Key Companies in the China Precision Medicine IndustryThe key manufacturers and service providers who have been contributing significantly to the china precision medicine market include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., BGI Genomics Co., Ltd., Illumina, Inc., Shanghai Fosun Pharmaceutical Group, WuXi AppTec, Berry Genomics Co., Ltd., Agilent Technologies, Inc., and PerkinElmer Inc., among others.

Read the full report: https://www.reportlinker.com/p05803973/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More here:
The China Precision Medicine Industry Analysis by BIS Research projects the market to grow at a significant CAGR of 12.82% during the forecast period,...

Global Strategic Analysis of the Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2020-2025 – Yahoo Finance UK

Posted on by

Dublin, June 12, 2020 (GLOBE NEWSWIRE) -- The "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market to 2025 - Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" report has been added to ResearchAndMarkets.com's offering.

This comprehensive report examines the precision medicine industry and its impact on the health system. This report tackles the growing market interest in pharmacogenomics, targeted therapeutics, companion diagnostics, and the associated market environment.

This report describes the current technologies that are propelling the personalized medicine and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in key markets such as the US, UK, Germany, and France are elucidated and analysed. This study reveals market figures of the overall personalized medicine market and also sub-market figures.

The study also provides a comprehensive financial and product review of key players in the personalized medicine industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the personalized therapeutic and associated companion diagnostic market have huge opportunities for growth. This industry is revolutionizing the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments.

The report is supported by over 360 tables & figures over 470 pages. The personalized medicine market is presented as follows:

A wealth of financial data & business strategy information is provided including:

SWOT, Economic & Regulatory Environment specifics include:

This report highlights a number of significant players and influential company's and gives details of their operations, products, financials and business strategy:

For more information about this report visit https://www.researchandmarkets.com/r/qmotdw

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Read more:
Global Strategic Analysis of the Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2020-2025 - Yahoo Finance UK

Gymnastic Equipment Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE – Cole of Duty

Posted on by

The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.

The global Gymnastic Equipment Market report scope includes detailed study covering underlying factors influencing the industry trends.

Browse Full Report: https://www.marketresearchengine.com/gymnastic-equipment-market

The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global Gymnastic Equipment Market share. Major industry players with significant revenue share include Abo, AK Athletic Equipment, Bnfer, Continental Sports, Norberts Athletic Products, and others.

The global Gymnastic Equipment Market is segregated on the basis of distribution channel as DTC, Modern trade, Online, and VAR. Based on Application the global Gymnastic Equipment Market is segmented in Hospital, Clinic, and Others. Based on Application the global Gymnastic Equipment Market is segmented in Infectious Diseases, Diabetes, Oncology, Cardiology, Autoimmune Diseases, Drug Testing/Pharmacogenomics, HIV/Aids, Nephrology, and Other Applications.

The global Gymnastic Equipment Market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The Gymnastic Equipment Market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.

Gymnastic equipment is intensely affected by an expansion in close to home interest in recreational sports exercises. The brisk face way of life of individuals has expanded the support of people engaged with different recreational exercises, and gymnastics is no exemption. Gymnastics as a recreational movement has increased huge footing as the number of individuals who want to take part in sports around the world over rises.

The expanding prominence of internet business directs to pick up footing in the market. The rising commonness of sedentary lifestyle and the absence of physical exercise are prompting a few physical and mental sicknesses, for example, diabetes, and hypertension, anxiety, obesity. Driven by the expanding familiarity with a healthy lifestyle. Moreover, there is a lofty increment in the number of individuals experiencing chronic back pain due to a lack of physical exercise. This will force individuals to concentrate on healthy fitness exercises which will drive the growth of the gymnastic equipment market globally.

Competitive Rivalry

Abo, AK Athletic Equipment, Bnfer, Continental Sports, Norberts Athletic Products, and others are among the major players in the global Gymnastic Equipment Market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.

The Gymnastic Equipment Market has been segmented as below:

Gymnastic Equipment Market, By Distribution Channel

Gymnastic Equipment Market, By Region

Gymnastic Equipment Market, By Company

The report covers:

Reasons to Buy this Report:

Request Sample Report from here: https://www.marketresearchengine.com/gymnastic-equipment-market

Table of Contents:

Other Related Market Research Reports:

Sarcoidosis Therapeutics Market 2019 Analysis Forecast Research and Development Report 2024

About MarketResearchEngine.com

Market Research Engine is a global market research and consulting organization. We provide market intelligence in emerging, niche technologies and markets. Our market analysis powered by rigorous methodology and quality metrics provide information and forecasts across emerging markets, emerging technologies and emerging business models. Our deep focus on industry verticals and country reports help our clients to identify opportunities and develop business strategies.

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: [emailprotected]

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

Excerpt from:
Gymnastic Equipment Market 2019 | How The Industry Will Witness Substantial Growth In The Upcoming Years | Exclusive Report By MRE - Cole of Duty

Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Virtual Annual Meeting II on June 22-24,…

Posted on by

BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced highlights from 12 presentations showcasing its research and development portfolio of novel targeted therapies and antibody-drug conjugate (ADC) technology advances and innovation will be presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting II being held June 22-24, 2020. Registration information to attend the virtual sessions can be found here.

We will have a strong presence at the AACR annual meeting with 12 data presentations highlighting our leadership in antibody-drug conjugate innovation and the depth and potential of our growing oncology pipeline of targeted therapies, said Scott Peterson, Ph.D., Senior Vice President of Research at Seattle Genetics. Of key importance, a number of presentations will feature advances in our drug linker and payload components of ADCs. Building on our expertise in CD30 targeted therapies, data will be presented from a new CD30-directed ADC that employs our novel camptothecin ADC technology and is being investigated as a potential future treatment option in CD30-expressing lymphomas.

Dr. Peterson added, In addition to our ADC technologies, we will also be presenting preclinical data highlighting the activity of our HER2 selective tyrosine kinase inhibitor tucatinib in preclinical models of HER2 mutant driven cancers and in the CNS setting. We look forward to sharing these presentations with the community at the second AACR virtual meeting.

Abstracts can be found at http://www.aacr.org and include the following poster presentations below.

New ADC Technology Advances

Abstract Title: Novel Framework for Quantifying Synergy in High-Throughput Drug Combination Cytotoxicity Experiments (Abstract #835)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Clinical and Preclinical Precision Medicine: Next-Generation Sequencing, Functional, and Pharmacogenomics

Abstract Title: Discovery of a Tripeptide-Based Camptothecin Drug-Linker for Antibody-Drug Conjugates with Potent Antitumor Activity and a Broad Therapeutic Window (Abstract #2885)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Antibody Drug Conjugates

Abstract Title: Characterization of Payload Release from a Novel Camptothecin Drug-Linker (Abstract #2895)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Antibody Drug Conjugates

Pipeline Programs

Abstract Title: SGN-CD30C, a New CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti-Tumor Activity and Superior Tolerability in Preclinical Studies (Abstract #2889)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Antibody Drug Conjugates

Abstract Title: Utilizing PDX Models to Better Understand Factors that Predict Response to SGN-CD228A, an Antibody-Drug Conjugate (ADC) for Solid Tumors (Abstract #2888)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Antibody Drug Conjugates

Abstract Title: SGN-B6A: A New MMAE ADC Targeting Integrin Beta-6 in Multiple Carcinoma Indications (Abstract #2906)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Antibody Drug Conjugates

Abstract Title: SEA-CD40 is a Non-Fucosylated Anti-CD40 Antibody with Potent Pharmacodynamic Activity in Preclinical Models and Patients with Advanced Solid Tumors (Abstract #5535)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Immune Response to Therapies 1

Commercial-Stage Programs

Abstract Title: Preclinical Characterization of Tucatinib in HER2-Amplified Xenograft and CNS Implanted Tumors (Abstract #1962)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Small Molecule Therapeutic Agents

Abstract Title: Tucatinib Inhibits Creatinine and Metformin Renal Tubule Secretion but has No Effect on Renal Function (GFR) (Abstract #3015)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Pharmacokinetics / Pharmacodynamics

Abstract Title: Tucatinib Inhibits CYP3A, CYP2C8 and P-gp-Mediated Elimination and is Impacted by CYP2C8 Inhibition in Healthy Volunteers (Abstract #3016)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Pharmacokinetics / Pharmacodynamics

Abstract Title: Tucatinib, a Selective Small Molecule HER2 Inhibitor, is Active in HER2 Mutant Driven Tumors (Abstract #4222)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Tyrosine Kinase and Phosphatase Inhibitors

Abstract Title: Enfortumab Vedotin, an Anti-Nectin-4 ADC Demonstrates Bystander Cell Killing and Immunogenic Cell Death Anti-Tumor Activity Mechanisms of Action in Urotherlial Cancers (Abstract #5581)Date and Time: Monday, June 22, 9:00 a.m.-6:00 p.m. PTSession: Immunotherapy

About Seattle Genetics

Seattle Genetics, Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in peoples lives. ADCETRIS (brentuximab vedotin) and PADCEV (enfortumab vedotin-ejfv) use the companys industry-leading antibody-drug conjugate (ADC) technology. ADCETRIS is approved in certain CD30-expressing lymphomas, and PADCEV is approved in certain metastatic urothelial cancers. TUKYSA (tucatinib), a small molecule tyrosine kinase inhibitor, is approved in certain HER2-positive metastatic breast cancers. The company is headquartered in the Seattle, Washington area, with locations in California, Switzerland and the European Union. For more information on our robust pipeline, visit http://www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the possible utility or application of the Companys technologies to develop therapeutic agents, the therapeutic potential of investigational agents and products, the Companys ADC leadership, future development activities and growing pipeline. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty and uncertainty of pharmaceutical product development, including the risks that the Company may experience delays in its planned clinical trial initiations or otherwise experience failures or setbacks in its preclinical and clinical development programs due to the potential lack of efficacy or risk of adverse events or other factors. More information about the risks and uncertainties faced by Seattle Genetics is contained under the caption Risk Factors included in the companys Quarterly Report on Form 10-Q for the quarter ended March 31, 2020 filed with the Securities and Exchange Commission. Seattle Genetics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Follow this link:
Seattle Genetics Antibody-Drug Conjugate Innovation and Targeted Therapy Programs to be Featured at the AACR Virtual Annual Meeting II on June 22-24,...

Pharmacogenomics Market 2027 : What are the best suggestions to maintain competiveness? – Cole of Duty

Posted on by

The Covid-19 (coronavirus) pandemic is impacting society and the overall economy across the world. The impact of this pandemic is growing day by day as well as affecting the supply chain. The COVID-19 crisis is creating uncertainty in the stock market, massive slowing of supply chain, falling business confidence, and increasing panic among the customer segments. The overall effect of the pandemic is impacting the production process of several industries including Life Science, and many more. Trade barriers are further restraining the demand- supply outlook.

Pharmacogenomics is an essential characteristic feature of precision medicine, which allows for an individuals genetic makeup affects and their response to a therapeutic drug. Although tailor-made medication dosing, there still are a large number of cases involving adverse drug reactions, leading to frequent dose titration and iteration concerning treatment. With all these things, these factors impose a significant burden on the patient, provider, and the overall healthcare system.

The pharmacogenomics market is expected to grow significantly in the coming years, owing to the key factors such as rising research and development activities by the major pharmaceutical companies, and increasing focus on precision medicine. The developing regions are likely to serve more growth opportunities in coming years due to increasing in strategic initiative taken by key players.

Download a Sample Report Explore further @https://www.theinsightpartners.com/sample/TIPRE00007564

Top Dominating Key Players:

1. Abbott.2. bioMrieux SA3. AstraZeneca4. Bayer AG5. BD6. Bio-Rad Laboratories, Inc.7. F. Hoffmann-La Roche Ltd8. Illumina, Inc.9. QIAGEN.10. Thermo Fisher Scientific Inc.

The global pharmacogenomics market is segmented on the basis of technology, application and end user. On the basis of technology, the market is segmented into DNA Sequencing, Microarray, Polymerase Chain Reaction, Electrophoresis, Mass Spectrometry, Others. Based on the application the market is divided into Drug Discovery, Neurology, Oncology, Pain Management, Other. On the basis of end user, the market is segmented into biopharmaceutical companies, clinical research organizations/contract research organizations, and contract development and manufacturing organization (CDMO).

The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the global Pharmacogenomics Market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Pharmacogenomics Market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.

The report analyzes factors affecting Pharmacogenomics Market from both demand and supply side and further evaluates market dynamics effecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Pharmacogenomics Market in these regions.

Request for Buy Report @https://www.theinsightpartners.com/buy/TIPRE00007564

Reasons to Buy the Report:

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

The Insight partners,

Phone: +1-646-491-9876Email:[emailprotected]

Read the original here:
Pharmacogenomics Market 2027 : What are the best suggestions to maintain competiveness? - Cole of Duty

Precision medicine guides choice of better drug therapy in severe heart disease – Science Codex

Posted on by

BIRMINGHAM, Ala. - Is personalized medicine cost-effective? University of Alabama at Birmingham researcher Nita Limdi, Pharm.D., Ph.D., and colleagues across the United States have answered that question for one medical treatment.

Patients experiencing a heart attack -- known as a myocardial infarction or an acute coronary syndrome -- have sharply diminished blood flow in coronary arteries, with a high risk of heart failure or death. Coronary angioplasty, a procedure to open narrowed or blocked arteries in the heart, and percutaneous coronary intervention, known as PCI or stenting, can restore blood flow to minimize damage to the heart. These procedures reduce the risk of subsequent major adverse cardiovascular events, or MACE, which include heart attacks, strokes or death.

But then, a treatment decision has to be made.

After stenting, all patients are treated with two antiplatelet agents for up to one year. Which combination of antiplatelets is best? The answer comes through pharmacogenomics, says Limdi, a professor in the UAB Department of Neurology and associate director of UAB's Hugh Kaul Precision Medicine Institute.

Pharmacogenomics combines pharmacology, the study of drug action, with genetics, the study of gene function, to choose the best medication according to each patient's personal genetic makeup. This is also called precision medicine -- tailored medical treatment for each individual patient.

The most commonly used antiplatelet combination after PCI is aspirin and clopidogrel, which is trademarked as Plavix. Clopidogrel is converted to its active form by an enzyme called CYP2C19. However, patients respond to clopidogrel differently based on their genetic makeup.

More than 30 percent of people have loss-of-function variants in the CYP2C19 gene that decrease the effectiveness of clopidogrel. The FDA warns that these patients may not get the full benefit of clopidogrel, which would increase the risk of MACE. So the FDA advises doctors to consider a different treatment such as prasugrel or ticagrelor, trademarked as Effient and Brillinta, to replace clopidogrel.

While most patients undergoing PCI receive clopidogrel without receiving any CYP2C19 loss-of-function testing, academic institutions like UAB that offer precision medicine use pharmacogenomics to guide the selection of medication dosing.

In 2018, Limdi and other investigators across nine United States universities -- all members of the Implementing Genomics in Practice consortium, or IGNITE -- showed that patients with loss-of-function variants who were treated with clopidogrel had elevated risks. There was a twofold increase in MACE risk for PCI patients, and a threefold increase in MACE risk among patients with acute coronary syndrome who received PCI, as compared to patients prescribed with prasugrel or ticagrelor instead of clopidogrel. Prasugrel and ticagrelor are not influenced by the loss-of-function variant and can substitute for clopidogrel, but they are much more costly and bring a higher risk of bleeding.

The IGNITE group then leveraged this real-world data to conduct an economic analysis to determine the best drug treatment for these heart disease patients.

A study led by Limdi and colleagues, published in the Pharmacogenomics Journal, examines the cost-effectiveness of genotype-guided antiplatelet therapy for acute coronary syndrome patients with PCI. This cost-effectiveness study is the first to use real-world clinical data; many cost-effectiveness studies use clinical trial data, which tends to exclude the sicker patients normally seen in clinical practice.

The study compared three main strategies: 1) treating all patients with clopidogrel, 2) treating all patients with ticagrelor, or 3) genotyping all patients and using ticagrelor in those with loss-of-function variants.

"We showed that tailoring antiplatelet selection based on genotype is a cost-effective strategy," Limdi said. "Support is now growing to change the clinical guidelines, which currently do not recommend genotyping in all cases. Evidence like this is needed to advance the field of precision medicine."

Costs, QALYs and ICERs

In the analysis, Limdi and colleagues considered differences in event rates for heart attacks and stent thrombosis in patients receiving clopidogrel versus ticagrelor versus genotype-guided therapy, during the one-year period following stenting. They also included medical costs from those events that are borne by the payer, such as admissions, procedures, medications, clinical visits and genetic testing. The analysis considered variations in event rates and medication costs over time to ensure that the results held under different scenarios.

The study uses an economic measure -- the QALY, which stands for the quality-adjusted life year.

"First, we looked at which strategy provided the highest QALY," Limdi said. "The QALY is the gold standard for measuring benefit of an intervention -- in our case, genotype-guided treatment compared to treatment without genotyping. Universal ticagrelor and genotype-guided antiplatelet therapy had higher QALYs than universal clopidogrel -- so those are the best for the patient."

But health care resources are not infinite. So, Limdi and colleagues then evaluated whether those interventions that have higher QALYs were also reasonable from a cost perspective. This analysis considered the willingness to pay. What would a payor or a patient pay for the highest QALY?

"In our case, the payor would recognize that ticagrelor is more expensive than clopidogrel -- $360 per month vs. $10 per month -- and there is a $100 cost for each genetic test," Limdi said. "So, from the payor perspective, the more effective strategy (one with a higher QALY) -- if more expensive (higher cost) -- would have to lower the risks of bad outcomes like heart attacks and strokes for the gains in QALY that are at, or below, the willingness-to-pay threshold."

A calculation called incremental cost-effectiveness ratios, or ICERs, assesses the incremental cost of the benefit (improvement in QALY). In the United States, a treatment is considered cost-effective if its associated ICER is at or below the willingness-to-pay threshold of $100,000 per QALY.

"In our assessment, the two strategies with the highest QALY had very different ICERs," Limdi said. "The genotype-guided strategy was cost-effective at $42,365 per QALY. Universal ticagrelor was not; it had an ICER of $227,044 per QALY."

The researchers also looked at some secondary strategies for a real-world reason. A number of clinicians now prescribe ticagrelor or prasugrel for the first 30 days after PCI, which is considered a period of greater risk, and then switch their patients to the less expensive drug clopidogrel.

The secondary analysis allowed Limdi and colleagues to explore the cost-effectiveness of giving all patients ticagrelor for 30 days, and then switching them to clopidogrel, without genetic testing, versus switching the patients based on genotype. Both strategies were better -- in terms of QALYs -- than a universal switch to clopidogrel at 30 days. However, neither of the two appeared to be cost-effective. Because these secondary strategies used estimated parameters, "the findings should only be considered as hypothesis-generating," Limdi said.

Link:
Precision medicine guides choice of better drug therapy in severe heart disease - Science Codex

AMP Expresses Support for Citizen Petition from the Coalition to Preserve Access to Pharmacogenomics Information – Newswise

Posted on by

Newswise ROCKVILLE, Md. May 4, 2020 The Association for Molecular Pathology (AMP), the premier global, molecular diagnostic professional society, today submitted a formal response in support of the Citizen Petition from Hyman, Phelps & McNamara, P.C. on behalf of the Coalition to Preserve Access to Pharmacogenomics (PGx) Information. The response builds on AMPs PGx Best Practices Statement and includes a series of recommendations that will rectify recent FDA actions, which have suppressed important patient safety information.

Clinical PGx testing services provide vital medical information that can aid healthcare providers with treatment selections for their patients. These tests are offered by highly qualified, board-certified molecular pathology professionals and are currently held to the same standards as all other laboratory developed testing procedures (LDPs). All supporting clinical validity evidence must be documented before the test is offered to patients. Recently, FDA took suppressive actions that limited the inclusion of clinical interpretation information in PGx test reports. These actions disregarded all of the qualifications of molecular professionals and the well-established clinical evidence for PGx testing. In its response in support of the Citizen Petition, AMP concluded that these actions were unlawful, infringed on the practice of medicine and threatened patient safety.

AMP is deeply concerned with the numerous examples of FDA overstepping its authority and employing haphazard approaches for regulating LDPs. In the past year, FDA has jeopardized patient safety with these suppressive actions for PGx tests and initially prevented qualified molecular professionals from developing, validating and performing assays to detect SARS-CoV-2 in patients at the onset of the COVID-19 pandemic, said Jordan Laser, MD, Medical Director of Long Island Jewish Medical Center Pathology and Laboratory Medicine, and Chair of AMP Professional Relations Committee. AMPs recommendations are based on our collective expertise in this rapidly developing field and reflect our ongoing commitment to improving professional practice and patient care.

The response to the Citizens Petition is another example of AMPs continuing work to engage key stakeholders as part of its efforts to improve clinical practice for pharmacogenomic tests. During the past year, AMP published a PGx Best Practices Statement and is also publishing a series of evidence-based expert consensus opinion recommendations for frequently used pharmacogenomic genotyping assays.

To read AMPs full response to the Citizen Petition on behalf of the Coalition to Preserve Access to PGx Information, please visit https://www.amp.org/AMP_Response_to_PGx_Citizen_Petition

To read AMPs full position statement on pharmacogenomic testing, please visit https://www.amp.org/PGxBestPracticesStatement.

ABOUT AMP

The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,500+ members practice various disciplines of molecular diagnostics, including bioinformatics, infectious diseases, inherited conditions, and oncology. Our members are pathologists, clinical laboratory directors, basic and translational scientists, technologists, and trainees that practice in a variety of settings, including academic and community medical centers, government, and industry.

Through the efforts of its Board of Directors, Committees, Working Groups, and Members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing. For more information, visit http://www.amp.org and follow AMP on Twitter: @AMPath.

Read this article:
AMP Expresses Support for Citizen Petition from the Coalition to Preserve Access to Pharmacogenomics Information - Newswise

WHITEHALL ANALYTICA THE AI SUPERSTATE: Part 2 Is COVID-19 Fast-Tracking a Eugenics-Inspired Genomics Programme in the NHS? – Byline Times

Posted on by

Nafeez Ahmed explores the troubling implications and assumptions of the Governments AI-driven gene programme.

In Part 1 of this investigation, I looked at how the convergence of an AI Superstate and corporate interests with health data lies at the heart of a new frontier for profit and surveillance. But the Governments response during the COVID-19 pandemic has revealed something even more profoundly disturbing: a fascination with genomics which moves from a merely descriptive tool to something so prescriptive it verges on eugenics.

The NHSX app is simply one project with a questionable design which appears to result from the Governments much wider project to remake the NHS.

At the core of the new NHSX AI drive is the goal of predictive, preventive, personalised and participatory medicine, according to an NHSX document published in October 2019. Pivotal to this AI-driven transformation is genetics:

Key to unlocking the benefits of precision medicine with AI is the use of genomic data generated by genome sequencing. Machine learning is already being used to automate genome quality control. AI has improved the ability to process genomes rapidly and to high standards and can also now help improve genome interpretation.

The NHS Genomic Medicine Service is starting with a focus on cancer, rare and inherited diseases,but its broader goal is far more comprehensive. Initially, the hope is that genomics will expand to cover other areas, such as pharmacogenomics, which looks at how an individuals genes influence a particular biological process that mediates the effects of a medicine, according to The Pharmaceutical Journal.

But the end-goal is to convert the NHS into a health service oriented fundamentally around the role of genetics in disease. The aspiration is that from 2020, and by 2025, genomic medicine will be an embedded part of routine care to enable better prediction and prevention of disease and fewer adverse drug reactions. The GMS aims to complete five million genomic analyses and five million early disease cohorts over the next five years.

By 2025, genomic technologies will be embedded through multiple clinical pathways and included as a fundamental part of clinical training. As a result, it is hoped that there will be a new taxonomy of medicine based on the underlying drivers of disease.

But, this entire premise is deeply questionable. There is little evidence that the underlying drivers of disease are primarily genetic.

Last December, a study in the journal PLOS One found that genetics usually explains no more than 5-10% of the risk for several common diseases. The study examined data from nearly 600 earlier studies identifying associations between common variations in the DNA sequence and more than 200 medical conditions. But its conclusion was stark: more than 95% of diseases or disease risks including Alzheimers, autism, asthma, juvenile diabetes, psoriasis, and so on could not be predicted accurately from the DNA sequence. A separate meta-analysis of two decades of DNA science corroborated this finding.

The implication is startling: that the entire premise for the billions of pounds this Government is investing in building a new privatised NHS infrastructure for AI-driven genomic medicine is scientifically unfounded.

The obsession with genetics can be traced directly back to the Prime Ministers chief advisor, Dominic Cummings.

Cummings set out his vision for the NHS in a February 2019 blog, which although previously reported on has not been fully appreciated for its astonishingly direct implications. While focusing on disease risk, the blog flagged-up Cummings hopes that a new NHS genomics prediction programme would ultimately allow the UK to, not just prevent diseases, but to do so before birth in effect a nod toward the selective breeding techniques at the core of eugenics.

They are using the COVID-19 crisis to erect a corporate superstate powered by mass surveillance and AI. Their grim ambition is to reach into the very DNA of every British citizen.

His vision for what a genomics-focused NHS would look like bears startling resemblance to the core ideas of eugenics the discredited pseudoscience aiming to improve the genetic quality of a human population by selecting for superior groups and excluding those with inferior genes. Its worst manifestations were exemplified by the Nazis.

In the blog, Cummings wrote:

Britain could contribute huge value to the world by leveraging existing assets, including scientific talent and how the NHS is structured, to push the frontiers of a rapidly evolving scientific field genomic prediction. He called for free universal SNP [single-nucleotide polymorphis] genetic sequencing as part of a shift to genuinely preventive medicine, to be rolled-out across the UK. This approach holds the promise of revolutionising healthcare in ways that give Britain some natural advantages over Europe and America.

Later in the post, Cummings allowed himself to speak more directly to what natural advantages could actually entail. He claimed that a combination of AI-driven machine learning with very large genetic sampling could enable the precise prediction of complex traits such as general intelligence and most diseases.

The two scientists Cummings cited as the primary sources for his vision were educational psychologist Robert Plomin and physicist Steven Hsu.

Plomin, described by Cummings as the worlds leading expert on the subject, is a renowned scientist. But he also has a history of association with the eugenics movement, according to Dr David King, founder of Human Genetics Alert and previously a molecular biologist. (Sir David King, the former chief scientific adviser to the UK Government, has also criticised the genome sequencing goldrush).*

When The Bell Curve a book advocating the genetic inferiority of African Americans was published, Plomin was a key signatory to a statement defending the science behind the book, explained Dr David King in a paper for the non-profit watchdog Human Genetics Alert. The statement carefully avoided explicitly endorsing The Bell Curves racist conclusions (aptly summarised by Francis Wheen as black people are more stupid than white people: always have been, always will be. This is why they have less economic and social success), while failing to repudiate them. Plomins fellow co-signatories included several self-proclaimed scientific racists, Philippe Rushton and Richard Lynn. Plomin has also published papers with the American Eugenics Society and spoken at several meetings of the British Eugenics Society (the latter rebranded itself as the Galton Institute in 1989) both of which advocated racial science.

In December 2013, Plomin was called as an expert witness to the House of Commons Education Select Committee, where he called for the Government to focus on the heritability of educational attainment. Twenty-five minutes into the session, Dominic Raab who as Foreign Secretary and First Secretary has stood in for Boris Johnson during his period of absence due to COVID-19 prompted Plomin to focus more specifically on explaining his views about genetics, intelligence and socio-economic status.

Just two months before Plomins parliamentary testimony, a 237-page dossier by Cummings then a top advisor to Education Secretary Michael Gove was leaked to the press. The paper claimed that genetics plays a bigger role in a childs IQ than teaching and called for giving specialist education as per Eton to the top 2% in IQ. Pete Shanks of the Centre for Genetics and Society described Cummings policy proposal as a blatantly eugenic association of genes with intelligence, intelligence with worth, and worth with the right to rule.

The Cummings dossier which cites Plomin extensively further reveals that, according to Cummings, he had invited Plomin into the DfE [Department for Education] to explain the science of IQ and genetics to officials and ministers.

The Education Select Committees report shows that, at the time of Plomins testimony, the Government was resistant to these views. But, the position appears to have changed since then, with figures such as Cummings, Raab and Gove now at the seat of power under Prime Minister Boris Johnson.

Plomin would go on to work with Steven Hsu, who was involved in a major Chinese genome sequencing project based on thousands of samples from very high-IQ people around the world. The goal was to identify genes that can predict intelligence. Hsu went on to launch his own company, Genomic Prediction. In slide presentations about his work from 2012, Hsu approvingly quoted British eugenicist Ronald Fisher, closing his slides with the following quotation: but such a race will inevitably arise in whatever country first sees the inheritance of mental characters elucidated. Hsus slides, wrote David King, include plans for a eugenic breeding scheme using embryo selection to improve the overall IQ of the population.

Yet, on his blog, Cummings confirmed that Hsu has recently attended a conference in the UK where he presented some of these ideas to UK policy-makers. Among the ideas Hsu presented to Cummings colleagues in Government was that the UK could become the world leader in genomic research by combining population-level genotyping with NHS health records. Hsu further claimed that risk prediction for common diseases was already available to guide early interventions that save lives and money.

Hopefully the NHS and Department for Health will play the Gretzky game, take expert advice from the likes of Plomin and Hsu and take this opportunity to make the UK a world leader in one of the most important frontiers in science, enthused Cummings.

Plomins claim that intelligence is determined primarily by genes contradicts a vast body of scientific literature, and is largely overblown. One of the latest studies debunking Cummings hopes was led by the University of Bristol and published in March. Based on a sample size of 3,500 children, the study found that polygenic scores (which combine information from all genetic material across the entire genome) have limited use for accurately predicting individual educational performance or for personalised education.

The study did not dismiss a role for genes outright, noting genetic scores modestly predictededucational achievement. The problem was that these predictions were less accurate than using standard information known to predicteducational outcomes, such as achievement at younger ages, parents educational attainment or family socio-economic position.

Last November, Hsus Genomic Prediction began touting new report cards to its customers. The cards displayed alleged results of genetic tests containing warnings that embryos might have low intelligence, grow up to be short, or have other conditions such as diabetes. But, according to the MIT Technology Review, the company has struggled both to validate its predictions and to interest fertility centres in them. In the month prior to Hsus grand announcement, the first major study to test the empirical viability of screening embryos, led by statistical geneticist Shai Carmi of the Hebrew University of Jerusalem, concluded that the technology is not plausible.

The lack of scientific substantiation has not stopped Cummings from suggesting a more interventionist vision for the NHS, which could be accused of paving the way for a new form of eugenics. In his February 2019 blog, he wrote: We can imagine everybody in the UK being given valuable information about their health for free,truly preventive medicinewhere we target resources at those most at risk, and early (evenin utero) identification of risks. This passage appears to nod to the core eugenics notion of selective breeding using embryo selection. Cummings even went further to endorse the goal of editing genes to fix problems.

In a further telling but slightly more well-known passage, Cummings characterised the genomics programme as a precursor to more realistic views about IQ and social mobility: It ought to go without saying that turning this idea into a political/government success requires focus on A) the NHS, health, science, NOT getting sidetracked into B) arguments about things like IQ and social mobility. Over time, the educated classes will continue to be dragged to more realistic views on (B) but this will be a complex process entangled with many hysterical episodes. (A) requires ruthless focus.

This passage affirms that Cummings approach is deliberately deceptive. The focus on health and the NHS is revealed as a cover for a longer-term vision to usher in more realistic views about things like IQ and social mobility. The passage also lifts the rock on Cummings weakest point that he fears that public attention on these more realistic views could sidetrack the broader strategy before it reaches fruition.

In the words of Dr David King, Cummings deference to Hsu, who openly advocated eugenics breeding programmes, suggests that the Prime Ministers chief advisor clearly favours this strategy for Britain; of course, this is precisely what all the European countries were trying to achieve in the heyday of eugenics to overcome their imperialist competitors by improving the national stock.

This, it seems, is the essence of Cummings ambition to use the NHS genomics prediction programme as a mechanism to provide Britain natural advantages over Europe and America.

And in this context, it is impossible to ignore the implications of Cummings appointment of Andrew Sabisky to a senior role advising Boris Johnson. When Johnsons spokespeople were asked repeatedly whether the Prime Minister would condemn Sabiskys sympathies for racist eugenics, he repeatedly refused. Sabisky later stepped away from the role.

The COVID-19 pandemic has now provided the Government with the opportunity to double down on its goals of extending genome sequencing across the UK population.

While genomic sequencing of the Coronavirus is undoubtedly an important scientific task to map and understand it, the crisis fits neatly into Cummings call for a ruthless focus on the NHS as a vehicle for Britains genetic enhancement.

On 23 March, when the UK finally instituted a lockdown at least three weeks after being informed that hundreds of thousands of people (and potentially up to a million) people were at risk of death from its previous policy of herd immunity, the Government launched a new scientific research consortium coordinated by Cambridge University along with the Wellcome Sanger Institute, the NHS and Public Health England.

The consortium would gather samples from patients confirmed with COVID-19 and send them to genetic sequencing centres across the country to analyse the whole genetic code of the samples. The project was billed breathlessly as an essential step in being able to control the pandemic and prevent further spread.

Unsurprisingly, it has done no such thing. Instead, six weeks later, the UK has ended up with the highest COVID-19 fatality rate in Europe.

As the death toll approaches the same level of British civilian casualties during the Second World War, the Governments strategy has privileged ambiguous, extortionate high technology solutions, pouring hundreds of millions of pounds into powerful private sector players with no transparency or due process. Meanwhile, traditional, proven, public health strategies such as better border controls, or extensive contact tracing and testing by scaling up local capacity, were inexplicably delayed for months.

On 13 March, the Government launched a new partnership between the NHS, Genomics England, the GenOMICC consortium, and US biotech giant Illumina, to conduct a nationwide human whole genome sequencing study targeting COVID-19 patients in 170 intensive care units.

The Governments new genome sequencing partner, Illumina, has previously produced genetic sequencing systems marketed to police agencies in China to facilitate its genetic profiling of the minority Uyghur population in Xinjang the largest system of discriminatory, ethnically-targeted biometric surveillance using DNA ever created.

It is difficult to avoid the conclusion that Dominic Cummings and his fellow ideologues in Government are hell-bent on pursuing a pseudo-scientific vision that has been years in the making.They are using the COVID-19 crisis to erect a corporate superstate powered by mass surveillance and AI. Their grim ambition is to reach into the very DNA of every British citizen.

Dominic Cummings was contacted for this article, but is yet to reply.

*This article was corrected to remove a confusion between Sir David King, the former government chief scientific adviser, and Dr David King, the molecular biologist who isthefounder and Director of Human Genetics Alert.

Read the original:
WHITEHALL ANALYTICA THE AI SUPERSTATE: Part 2 Is COVID-19 Fast-Tracking a Eugenics-Inspired Genomics Programme in the NHS? - Byline Times

Breaking the Code: A lifetime of pain, due to genetic drug intolerance – FirstCoastNews.com WTLV-WJXX

Posted on by

JACKSONVILLE, Fla. For Linda Armstrong, the pain started 25 years ago with a truck going 45 miles an hour. It left her with severe neurological and brain injuries.

On a scale of one to 10, she said, There are days when its 10. I mean you literally cant move.

Like millions of Americans, she was prescribed opioids -- Vicodin, Dilaudid, Percocet but the pain persisted.

I would get some relief, but nothing that ever really made me functional, she said, "and it always made me nauseous.

Armstrongs lackluster response to pain medications had been a reality since she was a child. Once, getting a cavity filled, she recalls, I had to have 10 shots for one filling because it just would not numb.

Her resistance to drugs was simply anecdotal until she visited her doctor in October. Under new Centers for Disease Control and Prevention guidelines, doctors test opioid patients both for the presence of illegal drugs, and to ensure they are taking and not selling their pain meds.

Her test? Completely negative. There were no drugs of any type in my system.

Initially, her doctor wrote it off as a fluke.

When it happened a second time, Armstrong explained, her doctor said Linda we have to talk about this.

She took another test this time going so far as to take pills while her doctor watched. She even got her hair tested.

Still: Negative.

Fortunately, Armstrong has had the same doctor since the mid-'90s, and rather than doubting her, she worked to help get answers. She ordered a genetic test, which revealed significant abnormalities -- including in an enzyme called CYP2d6, which metabolizes opioids.

The test revealed something researchers in the field of pharmacogenomics know, but few patients do. People do not respond to drugs in the same way, explains Standford University researcher Dr. Russ Altman in a Ted Talk. Some people get no pain relief at all.

Armstrongs genetic test showed she was a hyper-metabolizer of opioids an issue that creates problems beyond pain. As Altman says, there are only two things a doctor can think when a patient complains they arent getting relief from opioids.

I could think this person is a CYPD2d6 non-responder, or I could think this is a trouble-making drug-seeker who wants something stronger, Altman said. Most doctors think the latter.

Armstrongs case is dramatic but not unusual. Dr Liewei Wang at Mayo Clinic in Rochester, Minn., is a leading researcher in pharmacogenomics research into the interaction of genes and drugs. She says 99 percent of people have at least one genetic variant that affects drug response. Response is variable, and in some cases not desirable.

Genetic testing can predict who may or may not respond, she said, and for those who dont respond -- are there alternative therapies?

In some cases, the wrong drug can be fatal. Already, hospitals like UF Health test cardiac patients before surgery for a gene that complicates blood clotting.

And some fields, like oncology and psychiatry, routinely use genetic tests to prescribe drugs. But most patients arent aware such tests even exist.

Jacksonville Pharmacist Todd Troxell believes genetic testing is the key to more effective prescribing. When you go get your glasses we dont just say, pick something up and go home. We get your prescription, he says. You cant see out of myglasses.

After looking at Armstrongs test, Troxell was able to steer her to a different pain medication that is working. I could tell from what she had on her report she wasnt going to be able to take certain medications.

Troxell would like to see genetic testing more widely available -- and comprehensible. Companies focused on translating dense genetic code into pharmaceutical recommendations were effectively shut down by the FDA in 2018. The agency worriedthe tests could pose significant public health concerns as inaccurate test results could impact the decision-making of healthcare providers and patients in ways that are seriously detrimental to patient health.

The agency walked that back slightly earlier this year, creating a Table of Pharmacogenetic Associations, which lists gene-drug interactions the agency believes are based on sufficient scientific evidence based on published literature.

For now, a genetic test needs to be ordered by a physician, who may or may not be able to interpret the code. And genetics remains just one element that doctors and patients should consider, including age, weight and environmental factors.

But patients like Armstrong say breaking the genetic code shouldnt be a secret it could literally spare them a lifetime of pain. Given the chance early on, she said, I would have had that test done in a heartbeat.

See the rest here:
Breaking the Code: A lifetime of pain, due to genetic drug intolerance - FirstCoastNews.com WTLV-WJXX